SABS

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Retrieved on: 
Friday, March 29, 2024
Conference, Editas Medicine, Biotechnology, Exercise, Immunotherapy, Patient, Research, Investment, SABS, Therapy, JDRF, Safety, SAB, Type 1 diabetes, Cryptocurrency

We are grateful for their support in our drive to bring the benefits of SAB-142 to T1D patients in need.

Key Points: 
  • We are grateful for their support in our drive to bring the benefits of SAB-142 to T1D patients in need.
  • A replay of Mr. Reich’s presentation will be archived on the SAB Biotherapeutics website for up to one year.
  • SAB Biotherapeutics held cash and equivalents of $56.6 million at December 31, 2023, compared to $15.0 million at December 31, 2022.
  • SAB reported a net loss of $42.2 million and $18.7 million for the years ended December 31, 2023 and December 31, 2022 respectively.

NovalGen appoints Dr Michael Owen and Mr Scott Clark to the Board of Directors

Retrieved on: 
Monday, January 9, 2023
CRUK, Roche, Sanofi, SVP, University, London Business School, Therapy, Chemical engineering, New product development, Master of Science, Northwestern University, Biomedical Research, Biopharmaceutical, Berkeley, Medicine, Senior, Drug development, ReNeuron, Academy of Medical Sciences (United Kingdom), CSO, BS, University of Oxford, SABS, Acquisition, European, MBA, Doctor of Philosophy, GSK, Venture capital, BioMarin Pharmaceutical, University of Cambridge, Management, Fine chemical, Pharma, Biotechnology, Asota avacta

LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today announces the appointment of Dr Michael Owen and Mr Scott Clark as Non-Executive Directors to its Board, effective January 2023.

Key Points: 
  • LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today announces the appointment of Dr Michael Owen and Mr Scott Clark as Non-Executive Directors to its Board, effective January 2023.
  • Dr Owen is also an advisor to several Venture Capital LPs and is Chairman of Avacta plc’s SABs.
  • Prior to board services, Dr Owen co-founded and served as the first CSO of Kymab Ltd, a biopharmaceutical company recently acquired by Sanofi.
  • Prior to Tizona, Mr Clark was the Global Head of Oncology Partnering and Head of Asia and Emerging Markets Partnering at Roche.

South Africa Nappies and Other Disposable Textile and Paper Products Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 15, 2022
Other Manufacturing, Manufacturing, Mask, Health, South African Bureau of Standards, Kimberly-Clark, Prevalence, Contract, Supermarket, Procter & Gamble, Patriotism, Adult, Surge arrester, Infection, Corruption, Population growth, Population, Ageing, Sale, SABS, Growth, Urinary incontinence, Tissue paper, Pharmaceutical industry

The "Nappies and Other Disposable Textile and Paper Products in South Africa 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nappies and Other Disposable Textile and Paper Products in South Africa 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report focuses on nappies and other disposable textile and paper products including wipes, tampons, pads, surgical masks, and disposable clothing.
  • Although the sale of nappies increased in 2020, growth was lower than in 2019 as the pandemic resulted in financial pressure on consumers.
  • The pandemic magnified South Africa's dependence on imports for medical masks, gowns, aprons, and other textile-related outer protective clothing.

Kamran Tahamtanzadeh Joins Inanovate, Inc. as New Chief Executive Officer

Retrieved on: 
Tuesday, January 4, 2022
SABS, Growth, Cancer, Protein, Galena Biopharma, Breast cancer, CEO, Biomarker, Beckman, Diagnosis, Board, Â, GLOBE, Exosome, Technology, Founder CEO, Board of directors, Recurrence, Director, Roche, Medical imaging

Mr. Tahamtanzadeh is a highly passionate pharma-cancer diagnostics and digital health industry executive with nearly three decades of scientific, technology-product commercialization, M&A and investor relations experience.

Key Points: 
  • Mr. Tahamtanzadeh is a highly passionate pharma-cancer diagnostics and digital health industry executive with nearly three decades of scientific, technology-product commercialization, M&A and investor relations experience.
  • Kamran has performed numerous technology development and due diligence projects and has secured growth capital via private placements with angel investor groups and through strategic corporate venture funds.
  • Throughout his various executivepositions, Kamran has demonstrated atrack recordof success especially within companion diagnostics and cancer epigenetics fields.
  • -Kamran Tahamtanzadeh , CEO,Inanovate Inc.
    "We are delighted to welcome Kamran to the Inanovate team as our new CEO.

SEC Staff Issues Accounting Guidance on "Spring-Loaded" Compensation Awards to Executives

Retrieved on: 
Monday, November 29, 2021
SABS, U.S. Securities and Exchange Commission, Security (finance), Commission, SAB, Disclosure, Economics, SEC, Division, Corporate finance, Accounting, Financial adviser

Washington, D.C.--(Newsfile Corp. - November 29, 2021) - Securities and Exchange Commission staff today released guidance for companies about how to properly recognize and disclose compensation cost for "spring-loaded awards" made to executives.

Key Points: 
  • Washington, D.C.--(Newsfile Corp. - November 29, 2021) - Securities and Exchange Commission staff today released guidance for companies about how to properly recognize and disclose compensation cost for "spring-loaded awards" made to executives.
  • Spring-loaded awards are share-based compensation arrangements where a company grants stock options or other awards shortly before it announces market-moving information such as an earnings release with better-than-expected results or the disclosure of a significant transaction.
  • SEC staff believes that as companies measure compensation actually paid to executives, they must consider the impact that the material nonpublic information will have upon release.
  • "It is important that companies' accounting and disclosures reflect the economics and terms of these compensation arrangements," SEC Chair Gary Gensler said.